menu
    • menu
    [{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"DA01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"DA01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"DA01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"DA01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"BioCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"BlueRock Therapeutics \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BlueRock Therapeutics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bit Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"iPSC-derived T-cell Based Therapy","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"BlueRock Therapeutics \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Fujifilm Cellular Dynamics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"OpCT-001","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"BlueRock Therapeutics \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Dopamine producing neuron","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BlueRock Therapeutics

    Menu

    BlueRock Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BlueRock Therapeutics Advances Bemdaneprocel to Phase III Trial for Parkinson’s

                            Details : BRT-DA01 (bemdaneprocel) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 13, 2025

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BlueRock’s Bemdaneprocel Shows Positive Data at 24 Months for Parkinson’s Disease

                            Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 27, 2024

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BlueRock Therapeutics Gets FDA RMAT Designation for Parkinson’s Disease Cell Therapy

                            Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 31, 2024

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BlueRock's Phase I Trial for Parkinson’s Shows Positive Trends at 18 Months

                            Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 06, 2024

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OpCT-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Fujifilm Cellular Dynamics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BlueRock Exercise Option to License FUJIFILM's OpCT-001 for Primary Photoreceptor Disease

                            Details : Under the agreement, BlueRock exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for primary photoreceptor diseases.

                            Product Name : OpCT-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : OpCT-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Fujifilm Cellular Dynamics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BlueRock’s Phase I Study with Bemdaneprocel in Patients with Parkinson’s Disease Meets Primary Endpoint

                            Details : BRT-DA01 (bemdaneprocel) is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 02, 2023

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-derived T-cell Based Therapy

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Recipient : Bit Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BlueRock Therapeutics and Bit.Bio Announce Collaboration and Option Agreement for the Discovery and Manufactur...

                            Details : Under the agreement, bit.bio will use its machine learning powered discovery platform to identify transcription factor combinations for reprogramming iPSCs into Tregs, for the discovery and manufacture of iPSC-derived regulatory T cells for use in creati...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 03, 2023

                            Lead Product(s) : iPSC-derived T-cell Based Therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Recipient : Bit Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Bayer AG

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bluerock’s Neuronal Stem Cell Therapy for Parkinson’s Disease is First to Show Positive Results in Phase I...

                            Details : BRT-DA01 (bemdaneprocel), is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : Bemdaneprocel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Bayer AG

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : BioCardia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Pro...

                            Details : The agreement has an option to negotiate for a non-exclusive world-wide license to BioCardia biotherapeutic delivery product candidates for certain cell types for cardiac indications and is time limited.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 24, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : BioCardia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            BlueRock Therapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DA01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disea...

                            Details : The primary objective of the Ph1 trial is to assess the safety and tolerability of BRT-DA01 transplantation at one-year post-transplant. The secondary objectives are to assess the evidence of transplanted cell survival and motor effects at one- and two-y...

                            Product Name : BRT-DA01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : DA01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth